BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$7.65-1.67%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge BioCryst Pharmaceuticals, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-3.7%

+10% or more+5%0%−5%−10% or less

0.58 → 0.56 EPS · FY ending Dec 31, 2027 · 5 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 5 to 5; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	169.75M
EPS	—	0.109
Annual ending 2026-12-31
Revenue	—	710.08M
EPS	—	-2.292
Annual ending 2027-12-31
Revenue	—	742.66M
EPS	—	0.558

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Effective integration of Astria Therapeutics acquisition	The acquisition of Astria Therapeutics expands their pipeline.	Intact	Acquisition integration fails or pipeline expansion stalls in 2026	Qualitative: Integration advancing via external innovation shift Company shifted to external innovation, discontinued internal discovery, and achieved first profit, reinforcing strategic execution. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Non-GAAP operating expenses at or below $440M in 2026	They lowered operating expenses guidance to $420M-$440M, showing cost control.	Intact	Operating expenses exceed $440 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful restructuring to focus on rare disease pipeline	Restructuring focuses resources on rare disease drugs.	Intact	Restructuring delays or disrupts pipeline progress beyond 2026	Qualitative: Restructuring executed (Jun 2026) & pipeline advancing Board approved discontinuation of internal discovery in June 2026; Q2 2026 earnings beat estimates; company turned profitable. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain 2026 revenue between $635M and $660M	A primary condition in BioCryst Pharmaceuticals, Inc.'s published investment case. The stated target is >= $635 million.	Intact	Annual revenue falls below $635 million in FY26	Revenue: $218.25M FY2026-Q2; GAAP. Published target: >= $635 million. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026218,250,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 8aef6a52-db76-4e87-a207-93042567c6c3. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.56

Unavailable → $0.56 · observed estimates

FY2027 revenue$0.74B

$0.73B → $0.74B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$726,239,810	2 / 9
2026-07-25	Unavailable	$726,239,810	2 / 9
2026-07-26	Unavailable	$726,239,810	2 / 9
2026-07-27	$0.63	$734,899,528	5 / 7
2026-07-28	Unavailable	$726,239,810	2 / 9
2026-07-29	Unavailable	$726,239,810	2 / 9
2026-07-30	Unavailable	$726,239,810	2 / 9
2026-07-31	Unavailable	$726,239,810	2 / 9
2026-08-01	Unavailable	$726,239,810	2 / 9
2026-08-02	$0.63	$734,899,478	5 / 7
2026-08-03	Unavailable	$726,239,810	2 / 9
2026-08-04	Unavailable	$726,239,810	2 / 9
2026-08-05	Unavailable	$726,239,810	2 / 9
2026-08-06	Unavailable	$726,239,810	2 / 9
2026-08-07	Unavailable	$740,993,428	4 / 7
2026-08-08	Unavailable	$726,239,810	2 / 9
2026-08-09	Unavailable	$735,535,480	2 / 9
2026-08-10	Unavailable	$735,535,480	2 / 9
2026-08-11	Unavailable	$737,283,560	2 / 8
2026-08-12	Unavailable	$737,283,560	2 / 8
2026-08-13	Unavailable	$737,283,560	2 / 8
2026-08-14	Unavailable	$740,993,428	4 / 7
2026-08-15	Unavailable	$740,993,428	4 / 6
2026-08-16	Unavailable	$740,993,428	4 / 6
2026-08-17	Unavailable	$740,993,428	4 / 6
2026-08-18	Unavailable	$740,993,428	4 / 6
2026-08-19	Unavailable	$740,993,428	4 / 6
2026-08-20	Unavailable	$740,993,428	4 / 6
2026-08-21	$0.57	$740,993,378	5 / 6
2026-08-22	$0.58	$740,993,378	5 / 6
2026-08-23	$0.58	$740,993,378	5 / 6
2026-08-24	$0.58	$740,993,378	5 / 6
2026-08-25	$0.58	$740,993,378	5 / 6
2026-08-26	$0.58	$740,993,378	5 / 6
2026-08-27	$0.58	$740,993,378	5 / 6
2026-08-28	$0.58	$740,993,378	5 / 6
2026-08-29	$0.58	$740,993,378	5 / 6
2026-08-30	$0.58	$740,993,378	5 / 6
2026-08-31	$0.58	$740,993,378	5 / 6
2026-09-01	$0.58	$740,993,378	5 / 6
2026-09-02	$0.58	$740,993,378	5 / 6
2026-09-03	$0.58	$740,993,378	5 / 6
2026-09-04	$0.58	$740,993,378	5 / 6
2026-09-05	$0.58	$740,993,378	5 / 6
2026-09-06	$0.58	$740,993,378	5 / 6
2026-09-07	$0.58	$740,993,378	5 / 6
2026-09-08	$0.58	$740,993,378	5 / 6
2026-09-09	$0.58	$740,991,818	5 / 6
2026-09-10	$0.58	$740,991,818	5 / 6
2026-09-11	$0.58	$740,991,818	5 / 6
2026-09-12	$0.58	$740,991,818	5 / 6
2026-09-13	$0.58	$740,991,818	5 / 6
2026-09-14	$0.58	$740,991,818	5 / 6
2026-09-15	$0.58	$740,991,818	5 / 6
2026-09-16	$0.58	$740,991,818	5 / 6
2026-09-17	$0.58	$740,991,818	5 / 6
2026-09-18	$0.58	$740,991,818	5 / 6
2026-09-19	$0.58	$740,991,818	5 / 6
2026-09-20	$0.58	$740,991,818	5 / 6
2026-09-21	$0.58	$740,991,818	5 / 6
2026-09-22	$0.58	$740,991,818	5 / 6
2026-09-23	$0.58	$740,991,818	5 / 6
2026-09-24	$0.58	$740,991,818	5 / 6
2026-09-25	$0.58	$740,991,818	5 / 6
2026-09-26	$0.58	$740,991,818	5 / 6
2026-09-27	$0.58	$740,991,818	5 / 6
2026-09-28	$0.58	$740,991,818	5 / 6
2026-09-29	$0.58	$740,991,818	5 / 6
2026-09-30	$0.58	$740,991,818	5 / 6
2026-10-01	$0.58	$744,655,240	5 / 7
2026-10-02	$0.58	$744,655,240	5 / 7
2026-10-03	$0.58	$744,655,240	5 / 7
2026-10-04	$0.58	$744,655,240	5 / 7
2026-10-05	$0.58	$744,655,240	5 / 7
2026-10-06	$0.58	$744,655,240	5 / 7
2026-10-07	$0.58	$744,655,240	5 / 7
2026-10-08	$0.58	$744,655,240	5 / 7
2026-10-09	$0.58	$744,655,240	5 / 7
2026-10-10	$0.58	$744,655,240	5 / 7
2026-10-11	$0.58	$744,655,240	5 / 7
2026-10-12	$0.58	$744,655,240	5 / 7
2026-10-13	$0.58	$744,655,240	5 / 7
2026-10-14	$0.58	$744,655,240	5 / 7
2026-10-15	$0.58	$744,655,240	5 / 7
2026-10-16	$0.58	$744,655,240	5 / 7
2026-10-17	$0.58	$744,655,240	5 / 7
2026-10-18	$0.58	$744,655,240	5 / 7
2026-10-19	$0.58	$744,655,240	5 / 7
2026-10-20	$0.58	$744,655,240	5 / 7
2026-10-21	$0.59	$744,655,290	5 / 7
2026-10-22	$0.56	$742,655,290	5 / 7
2026-10-23	$0.56	$742,655,290	5 / 7
2026-10-24	$0.56	$742,655,290	5 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	10	0
2026-06-01	10	0
2026-07-01	10	1
2026-08-01	10	1
2026-09-01	10	2
2026-10-01	9	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Non-GAAP operating expenses at or below $440M in 2026Direct metric needs a verified mapping
Maintain 2026 revenue between $635M and $660MRevenue: $218.25M

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-31.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

BioCryst Pharmaceuticals, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a loss-making growth and restructuring story, not yet a proven durable compounder. The long-term thesis is intact, with recent financial performance holding in the top half of its industry, though management execution is rated volatile.

What's priced into BioCryst Pharmaceuticals, Inc.

The evidence describes BCRX as cheap versus peers, while also showing a 29% premium versus peers and an expectations gap of -0.42, so the valuation signals are mixed. The priced-in tag is justified and fragility is low, but the evidence does not specify exactly what growth expectations the market assumes.

What the fundamentals likely do

Near term, management has raised 2026 total revenue guidance to $690M-$715M while maintaining ORLADEYO guidance, and lowered non-GAAP operating expense guidance to $420M-$440M. Cost control and the shift away from internal discovery remain mixed, and the company is still loss-making. A 32% estimated miss probability is flagged as quiet, though recent peer misses add some risk.

What BioCryst Pharmaceuticals, Inc. hinges on

The multi-year view depends on maintaining the higher revenue outlook and delivering the planned cost reductions after restructuring. A guidance reversal would damage management credibility, while continued weakness in jobs data could weigh on cyclical names. Strong results and higher guidance from healthcare bellwethers could support the sector backdrop.